Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 45 of 46

Knowledge Gaps and Future Research Needs

The systematic review identified areas where evidence about the use of DMARDs to treat JIA is limited or absent, including:

  • The comparative effectiveness of DMARDs has rarely been examined in direct, head-to-head studies.
  • The effects of DMARDs on measures of inflammation and radiographic progression are unknown; their impact on JIA-associated conditions, such as uveitis and macrophage activation syndrome, has not been examined.
  • The evidence is too limited to understand how patient characteristics, disease subtype, and variability in the disease process affect response to treatment.
  • There are few high-quality data about the safety of DMARDs. Standardized definitions, measurement, and reporting of adverse effects associated with DMARDs are needed, together with long-term data collection.